The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma

SHIYUAN SONG1*, YING WANG1*, PO XU2*, RUINA YANG1, ZHIKUN MA1, SHUO LIANG1 and GUANGPING ZHANG1

Departments of 1Oncology, 2Urology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China

Received July 12, 2015; Accepted September 3, 2015

DOI: 10.3892/ijo.2015.3182

Abstract. Histone deacetylase 8 (HDAC8), a unique member of class I HDACs, shows remarkable correlation with advanced disease stage. The depletion of HDAC8 leads to inhibition of proliferation, apoptosis and cell cycle arrest in multiple malignant tumors. However, little is known about the contribution of HDAC8 to the tumorigenesis of gastric cancer (GC). The present study investigated expression of HDAC8 in GC cell lines and tissues, and the roles of HDAC8 inhibition in the proliferation, cell cycle and apoptosis of gastric cancer cells and explored the potential mechanisms. In the present study, quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), western blotting, and immunohistochemistry were used to examine the mRNA and protein expression of HDAC8 in GC cell lines and tissues. Then, the correlation between the clinicopathological parameters and the expression of HDAC8 was assessed. Finally, siRNA transfection and HDAC8 plasmid was performed to explore the functions of HDAC8 in GC progression in vitro. We found that the expression of HDAC8 was significantly upregulated both in GC cell lines and tumor tissues compared to human normal gastric epithelial cell, GES-1 and matched non-tumor tissues. Furthermore, depletion of HDAC8 remarkably inhibited GC cell proliferation, increased the apoptosis rate and G0/G1 phase percentage in vitro. Western blotting showed that the expression of protein promoting apoptosis such as, Bmf, activated caspase-3, caspase-6 were elevated following HDAC8 depletion. Our data exhibited an important role of HDAC8 in promoting gastric cancer tumorigenesis and identify this HDAC8 as a potential therapeutic target for the treatment of gastric cancer.

Introduction

Gastric adenocarcinoma (GC) is still one of the most common and aggressive carcinomas worldwide, especially in China where it ranks third in incidence and also third in mortality rate in malignant tumors, with 420,489 new cases and 297,496 deaths including 206,704 males and 90,792 females in 2011 (1). In the United States, the estimated new cases and deaths of gastric cancer are 24,590 and 10,720, respectively, in 2015 (2). Hence, the burden of gastric cancer is increasing. However, the mechanisms of the gastric cancer tumorigenesis is still unclear, to explore the molecular mechanism and therefore the potential therapeutic targets is of great importance for gastric cancer patients.

Epigenetic modifications have been found to be involved in the tumorigenesis, development and progression of gastric cancer, such as promoter DNA hypermethylation of tumor suppressors as well as post-translational alterations of histones (3). Previous studies showed that depletion of histone deacetylase is an effective way to inhibit the proliferation, promote cell cycle arrest and induce apoptosis of multiple malignant tumors (4), including breast (5), pancreatic (6), prostate (7), colorectal (8), hepatocarcinoma (9), lung cancer (10), leuchemia (11), gastric cancer (12), gliomas (13), and cervical cancer (14) which suggested that HDACs are the potential therapeutic targets for treatment of cancer.

The histone deacetylase (HDAC) family consists of 18 members (15), which are grouped into four separate classes, class I, HDAC1, HDAC2, HDAC3 and HDAC8; class II, HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10; class IV, HDAC11; and 7 sirtuins (4,16). The class I HDACs (HDAC1, 2, 3 and 8) are most closely related to the yeast (Saccharomyces cerevisiae) transcriptional regulator RPD3. HDACs function as key regulators of chromatin structure and post-translational modifiers of numerous key proteins in any cell type and tissue (4,17,18). Although HDAC1-3 and
6 were highlighted in most disease-oriented research (19), lately HDAC8 has become increasingly important as a drug target (20,21). HDAC8 is expressed in multiple adult malignant tumor entities, including lung, colon, pancreas and breast as well as in childhood tumor entities such as neuroblastoma (19). Depletion of HDAC8 by small interference RNA (siRNA) transfection inhibits proliferation of human lung, colon, and cervical cancer cell lines, moreover, the forced expression of HDAC8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma (22,23). It has been reported that HDAC8 mediated regulation of Bcl-2-modifying factor (BMF) via cooperation with STAT3 (24). BMF plays an important role in the execution of apoptosis triggered by the metabolite methylselenopyruvate, which is an inhibitor of HDAC8 (25). However, the expression, function and mechanism of HDAC8 in GC remain unclear.

In the present study, we found that the expression of HDAC8 was significantly upregulated both in GC cell lines and tumor tissues. HDAC8 knockdown significantly inhibited GC cell proliferation, induced cell cycle arrest and cell apoptosis. Furthermore, forced expression of HDAC8 promoted GC cell proliferation, inhibited cell cycle arrest and cell apoptosis. In addition, suppression of HDAC8 also resulted in the upregulation of BMF transcription followed by increased expression of cleaved caspase-3 and caspase-6.

Materials and methods

Ethics statement. Written informed consent was obtained from patients before obtaining tissue samples. The procedures used in the present study were approved by the Institutional Review Board of the First Affiliated Hospital, Henan University of Science and Technology and conformed to the Helsinki Declaration and to local legislation.

Patients and samples. GC tissues and their corresponding normal gastric tissues from 51 GC patients treated with surgery in 2008 in our hospital (First Affiliated Hospital, Henan University of Science and Technology, Henan, China) were enrolled in the present study. GC was confirmed by expert histopathologist examination in all these patients. The clinicopathological characteristics of the 57 patients with gastric cancer are shown in Table I.

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>N (%)</th>
<th>Relative expression (mean ± SEM)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>31 (60.8)</td>
<td>4.04±0.27</td>
<td>0.63</td>
</tr>
<tr>
<td>&lt;60</td>
<td>20 (39.2)</td>
<td>3.94±0.19</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>36 (70.6)</td>
<td>3.86±0.20</td>
<td>0.58</td>
</tr>
<tr>
<td>Female</td>
<td>16 (29.4)</td>
<td>4.06±0.28</td>
<td></td>
</tr>
<tr>
<td>Size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>29 (56.7)</td>
<td>5.20±0.24</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>&lt;5</td>
<td>22 (43.3)</td>
<td>2.42±0.027</td>
<td></td>
</tr>
<tr>
<td>Histological differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>17 (33.3)</td>
<td>2.12±0.11</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Moderately</td>
<td>17 (33.3)</td>
<td>4.03±0.23</td>
<td></td>
</tr>
<tr>
<td>Poorly</td>
<td>17 (33.3)</td>
<td>5.89±0.29</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>14 (27.5)</td>
<td>2.08±0.14</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Yes</td>
<td>37 (72.5)</td>
<td>4.72±0.26</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>12 (23.5)</td>
<td>2.04±0.14</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>II</td>
<td>18 (35.3)</td>
<td>3.84±0.17</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>21 (41.2)</td>
<td>5.32±0.26</td>
<td></td>
</tr>
</tbody>
</table>

expression was detected by PCR amplification of a 210-bp product with the primer pair: forward, 5'-TGGAGATCTCCAGAGGTGTC-3' and reverse, 5'-TCTTTGTAGATGCCCT-3'. PCR conditions were: 30 cycles and the temperature 60°C. GAPDH was used as the internal control. PCR products were separated on a 1.5% agarose gel stained with ethidium bromide and visualized with UV. RNA interference. siRNAs and negative control (Shanghai GenePharma Co., Ltd., Shanghai, China) were used to downregulate HDAC8 in BGC-823 and MKN28 cells using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. siRNAs sequences are as follows: siRNA-2 forward, 5'-UUGAGAUAACAAACACAGAU-3' and reverse, 5'-CUUCAUGUCUGCAAUCAUG-3'; NC siRNA forward, 5'-UCUCUGCCAGCUAGCUACGUTT-3' and reverse, 5'-ACUGACACGUCCAGAATT-3'.

Cells containing siRNA constructions were named siHDAC8 and siCtrl. Cells containing plasmid-HDAC8 (Guangzhou RiboBio Co., Ltd., Guangzhou, China) and the negative control (NC) (Guangzhou RiboBio) plasmid were named as the cell line-HDAC8 and the cell line-NC, respectively. Cells were plated into 6-well plates and the siHDAC8 and siCtrl were transfected into cells using transfection reagents when cells were 40% confluent. These cells were used for western blot analysis, qRT-PCR and in vitro experiments.
**MTT assay.** Cells were transfected with 100 nM miR-216b inhibitor (Shanghai GenePharma), mimics (Guangzhou RiboBio), or 100 nM siRNA-HDAC8 (Guangzhou RiboBio) as previously described (26), then seeded in 96-well plates (2x10^3/well) 24 h later. Cell viability was examined by the 3-(4,5-dimethylphenyl)-2,5-diphenyl tetrazolium bromide (MTT) assay (27-29) according to the manufacturer's instructions (Sigma, St. Louis, MO, USA) at designated times.

**Colony formation assay.** BGC-823 and MKN28 cells with or without HDAC8 knockdown or forced expression were seeded into 100-mm dishes at a density of 5,000 cells/well. After incubation for an additional 7 days, the cells were fixed with methanol for 15 min, and then stained with 0.1% crystal violet for another 15 min, and colonies of >50 cells were manually counted (30,31). The experiments were performed in independent triplicates.

**Cell cycle and apoptosis assay.** To detect cell cycle and apoptosis alterations, cells were grown in 6-well plates and treated with siHDAC8, siCtrl, HDAC8 or NC for 48 h. For cell cycle analysis, cells were harvested and fixed with ice-cold 75% ethyl alcohol at 4°C overnight and incubated with DNA Prep kit (Beckman Coulter, Fullerton, CA, USA) in the dark for 30-60 min. For apoptosis analysis, cells were harvested, washed twice using phosphate-buffered saline, and fixed in 70% ethanol at 4°C overnight. They were then incubated with propidium iodide at room temperature for 1 h and analyzed by flow cytometry using a FACScan flow cytometer (BD Biosciences, Mountain View, CA, USA). All the results were from 3 independent experiments.

**Western blot analysis.** Proteins from GC cell lines and paired fresh GC and tumor-adjacent normal gastric tissues were extracted with RIPA (Beyotime Institute of Biotechnology, Shanghai, China). The following process was carried out as described (15,32). The primary antibodies used for western blot analysis: HDAC8 (1:600, ab18968; Abcam), Bmf (1:500, ab9655; Abcam), caspase-3 (1:500, 710431; Thermo Fisher Scientific), caspase-6 (1:500, MA5-11527; Thermo Fisher Scientific).

**Immunohistochemistry.** Paraffin sections, 4-µm, were baked for 2 h at 65°C and deparaffinized. Antigen retrieval was performed using citrate sodium buffer (pH 7.2) at 95°C for 15 min and then slides were cooled at room temperature for 30 min. After being treated with 3% hydrogen peroxide for 15 min to block the endogenous peroxidase, the sections were treated with normal goat serum confining liquid for 30 min to reduce non-specific binding and then rabbit polyclonal anti-HDAC8 (1:200, ab18968; Abcam) was incubated the sections for 12 h at 4°C. After re-warming for 1 h and washing 5 times, sections were incubated with secondary antibody for 30 min at room temperature. Diaminobenzidine (DAB) was used for color reactions. Subsequent immunohistochemical staining was scored as previously described (33,34).

**Statistical analysis.** Data were expressed as means ± standard errors of three independent experiments. For statistical tests, we used the SPSS statistical software package, version 17.0 (SPSS, Inc., Chicago, IL, USA). The Student's t-test and the one-way analysis of variance (ANOVA) were performed to analyze relative band densities in western blotting and MTT optical density values. P-values <0.05 were considered statistically significant.

**Results**

**HDAC8 is upregulated in gastric cancer cell lines.** To further examine these findings, using western blotting experiments, we found that HDAC8 protein expression was also upregulated in 7 gastric cancer cell lines compared to GES-1 (P<0.0001), and was significantly higher in BGC823, AGS and GC9811 cell lines than in NCI-N87, SGC7901, MKN45 and MKN28 (Fig. 1A). To further investigate the expression pattern of HDAC8 in GC, we then performed qRT-PCR in these gastric cancer cell lines and GES-1. We found that HDAC8 mRNA expression was also significantly upregulated in all the gastric cancer cell lines compared to GES-1 (P<0.0001). Moreover, HDAC8 mRNA expression was significantly higher in poorly-differentiated cell lines BGC823, AGS and GC9811 (mean ± SEM, 8.43±0.9821), compared to other moderately and well-differentiated cell lines, SGC7901, MKN45, MKN28 and BGC823 (mean ± SEM, 3.5±0.5788) (P=0.0114) (Fig. 1B).
HDAC8 is upregulated in gastric cancer tissues. To examine HDAC8 expression in GC tissues, 51 cancer tissues, including 17 well, 17 moderately and 17 poorly differentiated tissues and matched non-tumor tissues were used. By qRT-PCR, we found that HDAC8 was significantly upregulated in 47 (92.2%) gastric cancer clinical tissues, compared with non-cancerous tissues (Fig. 2A). Then, HDAC8 expression was examined by immunohistochemistry and western blotting, which indicated that 45 and 44 patients had significantly upregulated HDAC8 expression, as detected by immunohistochemistry (Fig. 2B) and western blot analysis, respectively (Fig. 2C). To gain further insight into this observation, we examined the relationship between HDAC8 expression and the clinical parameters of the patients, and found that HDAC8 expression positively correlated with lymph node metastasis, tumor size, TNM stage and negatively with the histological differentiation (Table 1), but did not correlate with age or gender.

Depletion of HDAC8 inhibits proliferation in human gastric cancer cells in vitro. To investigate the role of HDAC8 in the proliferation of human gastric cancer cells, we used BGC823 and MKN28 cells to knockdown and overexpress HDAC8.
Using siHDAC8 or pcDNA3.1(+)−HDAC8 transfection which was followed with antibiotic selection to gain stable clones, we knocked down or upregulated HDAC8 expression. The expression levels were examined via western blotting (Fig. 3A) and qRT-PCR (Fig. 3B). As shown in Fig. 3C and D, using MTT method, we found that HDAC8 overexpression led to a significant increase in cell proliferation, while HDAC8 knockdown led to a significant decrease in cell proliferation. To further validate the function of HDAC8 in the GC proliferation, we performed plate colony experiments to assess the effect of depletion and upregulation of HDAC8 on the GC cell proliferation. We found that results of the
plate colony experiments were in line with that of the MTT assay (Fig. 3E and F).

**Knockdown of HDAC8 promoted G0/G1 arrest and apoptosis of gastric cancer.** To further study the mechanism by which HDAC8 knockdown or overexpression affected proliferation, cell cycle progression and apoptosis were analyzed using flow cytometry. The MKN28-siHDAC8 cells showed a delayed, while MKN28-HDAC8 exhibited a shortened G1 phase compared with corresponding control groups (Fig. 4A). Moreover, we also found that the apoptotic rates increased significantly in the MKN28-siHDAC8 group after siHDAC8 transfection was performed for 48 h, compared to the control group (Fig. 4B).

**Suppression of the HDAC8-induced upregulation of proteins involved Bmf-mediated apoptosis.** Previous studies showed that the HDAC8 inhibitor MSP triggers Bmf-mediated apoptosis independent of p21 induction via inducing of pro-apoptotic BMF expression (24). To investigate the apoptotic mechanism by which siHDAC8 induced apoptosis in more detail, several factors that are pro-apoptotic or indicative apoptotic were examined. In the present study, we first assessed Bmf, activated caspase-3, and activated caspase-6 using western blotting and found that Bmf, activated caspase-3, and activated caspase-6 were significantly upregulated when HDAC8 was downregulated (Fig. 5A). The qRT-PCR results were in line with that of western blotting (Fig. 5B).

**Discussion**

Epigenetics is the study of heritable alterations in gene expression that are not accompanied by the corresponding change in DNA sequence. There are three interlinked epigenetic processes which regulate gene expression at the level of chromatin, that is, DNA methylation, nucleosomal remodeling and histone covalent modifications. Post-translational modifications that occur on certain amino acid residues of the tails of
Figure 4. Depletion of HDAC8 significantly promoted G0/G1 arrest and apoptosis of the gastric cancer cell line MKN28. (A) G0/G1 phase percentage of examined MKN28 cells transfected with HDAC8 plasmid, siHDAC8 or controls after transfection was performed for 48 h. (B) Apoptosis rates of MKN28 cells treated with siHDAC8 or siCtrl at the designated time. Results in A and B are representative findings from three or more independent experiments, and all the values are shown as mean ± SEM, n=3.

Figure 5. The effect of RNAi HDAC8 on the expression of related downstream proteins causing apoptosis. (A) Western blotting assay and (B) mRNA examined by quantitative RT-PCR (qRT-PCR) of BMF, activated caspase-3, activated caspase-6. Results in A are representative findings from three or more independent experiments, and all the values are shown as mean ± SEM, n=3, tubulin served as a loading control (**P<0.0001).
SONG et al: HDAC8 FUNCTIONS AS AN ONCOGENE OF GC

Histone proteins modify the chromatin structure and form the basis for ‘histone code’. The level of acetylation of histones and then the gene expression is controlled by the enzymes histone acetyl transferase (HAT) and histone deacetylase (HDAC). It was shown that the balance between HAT and HDAC was altered in many cancers (35).

HDACs are widely involved in cellular processes, ranging from cell differentiation to proliferation, senescence, and apoptosis; in particular, protecting a telomerase activator from ubiquitin-mediated degradation. Studies have shown that HDAC8 could serve as the prognostic biomarker, promote tumorigenesis and progress in multiple tumors. For example, Wilmott et al (36) found that HDAC8 may be a prognostic biomarker in melanoma, and also provide important data regarding the regulation of HDACs in melanoma and a rational basis for targeting them therapeutically; Wu et al (22) reported that HDAC8 was overexpressed in HCC and HDAC8 knockdown could suppress tumor growth and enhance apoptosis in HCC via elevating the expression of p53 and acetylation of p53 at Lys382, indicating that HDAC8 might serve as a potential therapeutic target in HCC (37); Oehme et al (16) found that the knockdown of HDAC8 resulted in the inhibition of proliferation, reduced clonogenic growth, cell cycle arrest and differentiation in cultured neuroblastoma cells; Balasubramanian et al (38) reported that HDAC8-selective inhibitors had a unique mechanism of action involving PLCγ1 activation and calcium-induced apoptosis, and could offer benefits including a greater therapeutic index for treating T-cell malignancies. In the present study, we also found that depletion of HDAC8 using small interference RNA promoted apoptosis and cell cycle arrest in gastric cancer cells, moreover, forced expression of HDAC8 inhibited cell apoptosis and promoted cell proliferation, which suggested that HDAC8 may be a potential therapeutic target of gastric cancer.

Bmf, Bcl-2 modifying factor, is the closest relative of Bim (Bcl-2 interacting mediator of cell death) and functions as a tumor suppressor. A number of groups have demonstrated that overexpression of prosurvival Bcl-2 family members significantly reduces HDACi-mediated tumor cell death and therapeutic efficacy in preclinical models. In many cases, HDACi activate the intrinsic pathway via upregulation of a number of proapoptotic BH3-only Bcl-2 family genes including Bim, Bid and Bmf (39). Loss of bmf has been shown to accelerate the development of thymic lymphoma in a γ-irradiation carcinogenesis protocol in mice (40). BMF
gene silencing in HT29 cells lead to a decrease in oxaliplatin-induced cell death (41); Grab et al (42) found that GLI1/2 inhibitor GANT61 and PI3K/mTOR inhibitor PI103 cotreatment could increase mRNA and protein expression of NOXA and BMF, which is required for apoptosis, since knockdown of NOXA or BMF significantly reduces GANT61/PI103-induced apoptosis. It has been reported that HDAC8 mediated regulation of Bcl-2-modifying factor (BIM) via cooperation with STAT3. Here, we reported that inhibition of HDAC8 led to increased apoptosis rate of gastric cancer cells accompanied by the enhanced expression of Bmf, activated caspase-3 and activated caspase-6 (Fig. 6).

In summary, in the present study, we demonstrated that HDAC8 was significantly upregulated in GC tissues and gastric cancer cells, and inhibition of HDAC8 inhibited cell proliferation and enhanced apoptosis. Moreover, we found that depletion of HDAC8 enhanced expression of Bmf, which is a tumor suppressor via inducing apoptosis. Our novel evaluation of HDAC8 in gastric adenocarcinoma may suggest new effective therapeutic strategies in GC.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (no. 81301763 and no. 81572849) and the Henan Provincial Key Scientific and Technological Projects (no. 142102310473).